Loading…
Loading…
VTAK does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for VTAK and 80,000+ other tickers.
See exactly how VTAK's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for VTAK and 80,000+ other tickers.
Catheter Precision, Inc., headquartered in Fort Mill, South Carolina, is dedicated to creating and distributing electrophysiology products. Their mission is to enhance treatment and outcomes for U.S. patients suffering from cardiac arrhythmias by providing innovative technologies and solutions to patients, hospitals, and physicians. Their premier product, the View into Ventricular Onset System (VIVO), is a non-invasive 3D cardiac mapping solution designed to accurately locate the origin points of idiopathic ventricular arrhythmias in patients with otherwise healthy hearts, before they undergo…
Received First LockeT Purchase Order Through Cardinal Health which serves approximately 90% of U.S. Hospitals though its Medical Products business
New Account Creation Increased 170% During the First 17 Days of August Compared to the Same Period in July Flyte Has Added More Accounts Since July 1 Than During the Entire First Half of 2026 Growing First-Party Customer Base Now Spans 174 Airports Across 19 States FORT MILL, S.C., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Flyte, a subsidiary of Catheter Precision, Inc. (NYSE American: VTAK) (“VTAK” or the “Company”), today announced that more than 10,000 consumer accounts are now registered on the Flyte WebApp, marking a significant milestone as new account creation continues to accelerate across the Company's technology-enabled private aviation platform.
Strategic Partnership Positions Flyte as the Premier Regional Aviation Solution for Statewide Campaigns While Expanding Access to More Than 5,000 Candidates, SuperPACs and Political Organizations
Strategic Partnership Places Flyte at the Center of One of the Nation's Premier Communities of Founders, Investors, and Operators Collaboration Reflects Flyte's Continued Commitment to Building Relationships Within the Entrepreneurial and Venture Capital Ecosystem FORT MILL, S.C., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Flyte, a subsidiary of Catheter Precision, Inc. (NYSE American: VTAK) ("VTAK" or the "Company"), today announced a strategic partnership with The Nucleus Network, a rapidly growing community connecting founders, investors, executives, and innovators, to support the inaugural "The Nucleus" event taking place August 15th at 4:00 p.m.
July 2026 Revenue Increased 102% sequential July Over June to Approximately $640,000 Retail Platform, Strategic Partnerships and Influencer Marketing Fuel Accelerating Growth FORT MILL, S.C., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Flyte, a subsidiary of Catheter Precision, Inc. (NYSE American: VTAK) (“VTAK”), today announced record monthly revenue for July 2026, marking the strongest operating month in Flyte's history as demand continues to accelerate across its private aviation platform.